Hematologic toxicities of sunitinib in patients with gastrointestinal stromal tumors: a systematic review and meta-analysis

被引:0
作者
Xuehui Jiang
Fangfang Xiong
Qun Fu
Hongwei Peng
Yan Jing
Kaisaner Rexiti
Xiaohua Wei
Song Tao
机构
[1] Nanchang University,School of Pharmacy
[2] the First Affiliated Hospital of Nanchang University,Department of Pharmacy
[3] Fujian Medical University,School of Pharmacy
[4] Linyi Central Hospital,Department of Pharmacy
来源
International Journal of Colorectal Disease | 2022年 / 37卷
关键词
Sunitinib; GIST; Hematologic toxicities; Meta-analysis;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:1525 / 1534
页数:9
相关论文
共 171 条
[1]  
Blay JY(2021)Gastrointestinal stromal tumours Nat Rev Dis Primers 7 22-580
[2]  
Kang YK(1998)Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors Science (New York, NY) 279 577-710
[3]  
Nishida T(2003)PDGFRA activating mutations in gastrointestinal stromal tumors Science (New York, NY) 299 708-5202
[4]  
von Mehren M(2018)Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in gastrointestinal stromal tumors World J Gastroenterol 24 5189-323
[5]  
Hirota S(2019)Cytoreductive surgery for metastatic gastrointestinal stromal tumors followed by sunitinib compared to followed by imatinib-a multi-center cohort study Eur J Surg Oncol 45 318-761
[6]  
Isozaki K(2022)Gastrointestinal stromal tumors: what is the best sequence of TKIs? Curr Treat Options Oncol 23 749-215
[7]  
Moriyama Y(2021)Dual EGFR-VEGF pathway inhibition: a promising strategy for patients with EGFR-mutant NSCLC J Thorac Oncol 16 205-33
[8]  
Heinrich MC(2022)Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS clinical practice guidelines for diagnosis, treatment and follow-up Ann Oncol 33 20-5359
[9]  
Corless CL(2008)Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor J Clinic Oncol : Official J Am Soc Clinic Oncol 26 5352-1104
[10]  
Duensing A(2009)Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial Lancet (London, England) 373 1097-1069